-- E.J. Mundell
TUESDAY, Aug. 27 (HealthDay News) -- Patients with the common
skin condition rosacea can now turn to the first topical gel aimed
at easing the redness that comes with the ailment.
The U.S. Food and Drug Administration on Monday approved Mirvaso
(brimonidine) for the treatment of the redness -- clinically known
as erythema -- that is a hallmark of rosacea. The gel is made by
Galderma Laboratories, of Fort Worth, Texas, and was approved based
on two month-long clinical trials involving more than 550
"Facial redness is the most common symptom of rosacea, but until now, physicians have been without prescription treatment options to specifically address this patient need," lead investigator Dr. Mark Jackson, a dermatologist and clinical professor of medicine at the University of Louisville in Kentucky, said in a news release from Galderma.
"The FDA approval of Mirvaso marks a turning point in rosacea treatment: we are now able to provide patients that deal with the daily frustrations caused by the redness of rosacea with an effective therapy," he said.
One skin expert not connected to the company agreed.
"Up until this point, we have only had drugs to treat the bumps and pus pimples of rosacea," said Dr. Joshua Zeichner, director of cosmetic and clinical research in the department of dermatology at Mount Sinai Medical Center, in New York City. "The approval of Mirvaso is very exciting because for the first time, we have a medication to treat facial redness of rosacea, which previously could only be addressed with lasers. Facial redness is a significant issue for rosacea patients, so this drug will fill a large, unmet need."
Rosacea is a chronic inflammatory and vascular ailment that
affects the face, causing redness and visible blood vessels as
blemishes appear on the forehead, nose and cheeks. The condition is
most common in people over 30 and is thought to affect about 16
million Americans, according to the news release.
The studies that led to Mirvaso's approval showed that the drug
outperformed an inactive placebo gel in providing "significantly
greater improvement in the facial redness of rosacea," the Galderma
release said. Another trial, involving 276 patients, was conducted
for a year.
According to the company, Mirvaso is thought to work by
constricting otherwise dilated facial blood vessels, cutting down
on the appearance of redness. The gel is applied once a day to the
forehead, chin, nose and cheeks, Galderma said. It will be
available in pharmacies in September.
Another dermatologist cautioned that Mirvaso should not be seen
as a cure for rosacea.
"This will not replace the need for other rosacea treatments for control of breakouts," said Dr. Doris Day, a dermatologist at Lenox Hill Hospital in New York City. However, she said, existing rosacea therapies "have been limited in their ability to treat or control redness."
Side effects from Mirvaso were rare. In the year-long study,
less than 4 percent of the patients experienced reactions such as
flushing, redness, burning sensations or headache, the company
said. The gel is currently indicated for adults aged 18 or older,
and should only be used "with caution" by people affected by
depression or certain heart or autoimmune disorders.
To find out more about rosacea, head to the
EBSCO Information Services is fully accredited by URAC. URAC is an independent, nonprofit health care accrediting organization dedicated to promoting health care quality through accreditation, certification and commendation.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Information Services. All rights reserved.